购物车
- 全部删除
- 您的购物车当前为空
ERK5-IN-1 是 ERK5抑制剂,IC50为 87 nM。它也抑制 LRRK2[G2019S],IC50为 26 nM。
ERK5-IN-1 是 ERK5抑制剂,IC50为 87 nM。它也抑制 LRRK2[G2019S],IC50为 26 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 495 | 现货 | |
5 mg | ¥ 1,230 | 现货 | |
10 mg | ¥ 1,730 | 现货 | |
25 mg | ¥ 2,980 | 现货 | |
50 mg | ¥ 4,350 | 现货 | |
100 mg | ¥ 6,470 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 1,260 | 现货 |
产品描述 | ERK5-IN-1 is a potent ERK5 inhibitor (IC50: 87 nM). It also inhibits LRRK2[G2019S] (IC50: 26 nM). |
靶点活性 | ERK5:87 nM (cell free) |
体外活性 | ERK5-IN-1能够抑制HeLa细胞中由EGF刺激的ERK5自磷酸化(EC50:0.19 μM)。 |
激酶实验 | Kinase activity was determined in an assay volume of 40 μL in kinase buffer (50 mM Tris–HCl, pH 7.5, 0.1 mM EGTA, 1 mM 2-mercaptoethanol) containing 200 ng of pure active ERK5 and the indicated amount of inhibitor. Reaction started by adding 10 mM magnesium acetate, and 50 μM [γ-32P]-ATP (500 cpm/pmol) and 250 μM PIMtide (ARKKRRHPSGPPTA) as substrates. Assays were carried out for 20 min at 30 °C, terminated by applying the reaction mixture onto p81 paper and the incorporated radioactivity measured as described previously. |
细胞实验 | HeLa cells were serum starved overnight followed by treatment with inhibitors for 1 h. Cells were then stimulated with EGF (20 ng/mL) for 17 min and harvested in RIPA buffer (1× PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 0.1 mg/ml PMSF and 1 mM sodium orthovanadate). Proteins from total cell lysates were resolved by 6% sodium dodecyl sulfate (SDS)-poly-acrylamide gel electrophoresis (PAGE), transferred to nitrocellulose membrane, blocked in 5% nonfat milk, and blotted with anti-ERK5 antibody. |
分子量 | 459.54 |
分子式 | C25H29N7O2 |
CAS No. | 1234479-76-5 |
Smiles | COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1 |
密度 | 1.268 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 25 mg/mL (54.4 mM) | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容